FDA's Establishment of QSP-Based Immunomodulatory Drug Dosage Guidelines is Expected to Benefit Companies Like Certara (CERT).
1. Transition to a Clinical Paradigm Through the Introduction of Quantitative Systems Pharmacology (QSP)
The U.S. Food and Drug Administration (FDA) announced a draft guideline (Docket No. FDA-2026-D-6539) on June 24, 2026, introducing Quantitative Systems Pharmacology (QSP) modeling to determine a safe starting dose in First-in-Human (FIH) trials. The previous method, based on the No Observed Adverse Effect Level (NOAEL) in animals, has shown significant limitations in predicting the toxicity of complex biologics in humans. QSP is an innovative technology that uses computer simulations to mathematically reproduce the interaction between biological systems and drugs, thereby increasing the predictive power of early-stage clinical trials. This regulatory change is expected to serve as a catalyst for global biotech companies to adopt data-driven, precise clinical trial designs.
2. Maximizing the Efficiency of Calculating the Minimum Anticipated Biological Effect Level (MABEL)
The core of this guideline is the recommendation to apply QSP techniques when setting the Minimum Anticipated Biological Effect Level (MABEL). Following the 2006 clinical trial disaster involving TeGenero's CD28-targeting antibody 'TGN1412', MABEL was introduced to ensure safety. However, this resulted in overly conservative dosage settings, leading to situations where patients did not experience therapeutic benefits, wasting time and resources. By utilizing QSP simulations, it is possible to accurately predict the dose-response relationship of a drug, ensuring safety while also determining a scientifically sound starting dose. This contributes to increasing the success rate of early-stage clinical trials and optimizing the development timeline.
3. Development of Highly Complex Pipelines Centered on Bispecific Antibodies and Immunomodulatory Therapies
The trend in new drug development is rapidly shifting towards highly complex immunomodulatory drugs such as bispecific antibodies and T-cell engagers. These drugs carry a high risk of inducing life-threatening Cytokine Release Syndrome (CRS), making it difficult to ensure safety based solely on animal experiments. To address these risks, the FDA recommends using QSP models with sensitivity analysis and uncertainty assessment, encouraging development companies to proactively identify toxicity thresholds. As a result, QSP capabilities are expected to become an essential requirement for new drug approvals for companies developing immunological targets.
4. Growth of the Biosimulation Market and Optimization of New Drug R&D Costs
This regulatory change will inevitably drive the growth of the Model-Informed Drug Development (MIDD) software and consulting market. The global QSP platform market is projected to grow from $388.5 million in 2025 to approximately $1.19 billion in 2034, with an annual growth rate of 13.2%. As a result, companies like Certara (CERT) and Simulations Plus (SLP), which hold a market share of 35-40%, are expected to see increased revenue. Pharmaceutical companies can also expect to shorten the average program duration by 10 months and reduce R&D costs by $5 million per program.
The FDA's establishment of QSP-based MABEL guidelines is a significant regulatory milestone aimed at increasing the success rate of new drug development in Phase 1 clinical trials and maximizing R&D productivity. In the short term, it will serve as a catalyst for biotech companies with pipelines of bispecific antibodies or T-cell engagers, which carry a high risk of non-specific immune activation, to obtain reliable human dose prediction data. In the medium to long term, it is expected to significantly increase the commercial value of Certara (CERT) and Simulations Plus (SLP), which have secured a dominant position in the global QSP platform market, estimated at $388.5 million in 2025. Furthermore, pharmaceutical companies will be able to achieve R&D budget efficiency by shortening clinical development timelines by an average of 10 months and reducing costs by more than $5 million per program. As a result, the combination of regulatory science and computer simulation technology will elevate the risk management level of the entire bio-investment ecosystem.